The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.

Adenocarcinoma of Lung / drug therapy Aminopyridines / pharmacology Animals Carcinoma, Non-Small-Cell Lung / drug therapy Cell Line, Tumor Cell Transformation, Neoplastic / drug effects Chromosomes, Human, Pair 12 / genetics Chromosomes, Human, Pair 15 / genetics Humans Lactams / pharmacology Lung Neoplasms / drug therapy Mice Mice, Nude Microtubule-Associated Proteins / genetics Neoplasm Proteins / genetics Oncogene Proteins, Fusion / genetics Pyrazoles / pharmacology Receptor Protein-Tyrosine Kinases / genetics Xenograft Model Antitumor Assays

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
12 2021

Historique:

received: 27 05 2021

accepted: 13 10 2021

pubmed: 26 11 2021

medline: 1 3 2022

entrez: 25 11 2021

Statut: ppublish

Résumé

Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by oncogenic drivers have substantially improved therapeutic outcomes in patients with non-small-cell lung cancer (NSCLC)

Identifiants

DOI: 10.1038/s41586-021-04135-5 PMID: 34819663 PMC: PMC8687755

pubmed: 34819663

doi: 10.1038/s41586-021-04135-5

pii: 10.1038/s41586-021-04135-5

pmc: PMC8687755

mid: NIHMS1760523

doi:

Substances chimiques

Aminopyridines 0

Lactams 0

Microtubule-Associated Proteins 0

Neoplasm Proteins 0

Oncogene Proteins, Fusion 0

Pyrazoles 0

cytoplasmic linker protein 170 148349-95-5

LTK protein, human EC 2.7.10.1

Receptor Protein-Tyrosine Kinases EC 2.7.10.1

lorlatinib OSP71S83EU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

319-323

Subventions

Organisme : NCI NIH HHS

ID : R01 CA240257

Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Konig, D., Savic Prince, S. & Rothschild, S. I. Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers 13, 713 (2021).

doi: 10.3390/cancers13040804

Saito, M. et al. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 107, 713–720 (2016).

doi: 10.1111/cas.12941

The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).

doi: 10.1038/nature13385

Fernandez-Cuesta, L. et al. CD74–NRG1 fusions in lung adenocarcinoma. Cancer Discov. 4, 415–422 (2014).

doi: 10.1158/2159-8290.CD-13-0633

Non-small cell lung cancer version 4.2021 National Comprehensive Cancer Network https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (2021).

Roll, J. D. & Reuther, G. W. ALK-activating homologous mutations in LTK induce cellular transformation. PLoS ONE 7, e31733 (2012).

doi: 10.1371/journal.pone.0031733

Scheel, J. et al. Purification and analysis of authentic CLIP-170 and recombinant fragments. J. Biol. Chem. 274, 25883–25891 (1999).

doi: 10.1074/jbc.274.36.25883

Grigoryan, G. & Keating, A. E. Structural specificity in coiled-coil interactions. Curr. Opin. Struct. Biol. 18, 477–483 (2008).

doi: 10.1016/j.sbi.2008.04.008

Varmus, H. E. The molecular genetics of cellular oncogenes. Annu. Rev. Genet. 18, 553–612 (1984).

doi: 10.1146/annurev.ge.18.120184.003005

Warmuth, M., Kim, S., Gu, X. J., Xia, G. & Adrián, F. Ba/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19, 55–60 (2007).

doi: 10.1097/CCO.0b013e328011a25f

Soda, M. et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).

doi: 10.1038/nature05945

Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313 (2005).

doi: 10.1371/journal.pmed.0020313

Kobayashi, S. et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096–7101 (2005).

doi: 10.1158/0008-5472.CAN-05-1346

Yasuda, H. et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 5, 216ra177 (2013).

doi: 10.1126/scitranslmed.3007205

Zou, H. Y. et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28, 70–81 (2015).

doi: 10.1016/j.ccell.2015.05.010

Yamada, S. et al. Expression of a chimeric CSF1R–LTK mediates ligand-dependent neurite outgrowth. Neuroreport 19, 1733–1738 (2008).

doi: 10.1097/WNR.0b013e3283186bf8

Bruno, R. & Fontanini, G. Next generation sequencing for gene fusion analysis in lung cancer: a literature review. Diagnostics 10, 521 (2020).

doi: 10.3390/diagnostics10080521

Kohno, T. et al. Beyond ALK–RET, ROS1 and other oncogene fusions in lung cancer. Transl. Lung Cancer Res. 4, 156–164 (2015).

pubmed: 25870798 pmcid: 4384213

The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014).

doi: 10.1016/j.cell.2014.09.050

Yoshihara, K. et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 34, 4845–4854 (2015).

doi: 10.1038/onc.2014.406

Muller-Tidow, C. et al. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin. Cancer Res. 10, 1241–1249 (2004).

doi: 10.1158/1078-0432.CCR-0954-03

Carvalho, P., Gupta, M. L., Jr., Hoyt, M. A. & Pellman, D. Cell cycle control of kinesin-mediated transport of Bik1 (CLIP-170) regulates microtubule stability and dynein activation. Dev. Cell 6, 815–829 (2004).

doi: 10.1016/j.devcel.2004.05.001

Drilon, A. et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 17, 1653–1660 (2016).

doi: 10.1016/S1470-2045(16)30562-9

Kuroda, N. et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod. Pathol. 33, 2564–2579 (2020).

doi: 10.1038/s41379-020-0578-0

Pinsolle, J. et al. A rare fusion of CLIP1 and ALK in a case of non-small-cell lung cancer with neuroendocrine features. Clin. Lung Cancer 20, e535–e540 (2019).

doi: 10.1016/j.cllc.2019.05.001

Yeh, I. et al. Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. Am. J. Surg. Pathol. 39, 581–591 (2015).

doi: 10.1097/PAS.0000000000000387

Gainor, J. F. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6, 1118–1133 (2016).

doi: 10.1158/2159-8290.CD-16-0596

Haas, B. J. et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 20, 213 (2019).

doi: 10.1186/s13059-019-1842-9

Pear, W. S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780–3792 (1998).

doi: 10.1182/blood.V92.10.3780

Borowicz, S. et al. The soft agar colony formation assay. J. Vis. Exp. (92), e51998 (2014).

Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148–154 (1989).

doi: 10.1007/BF00300234